CIK 0000914475 · Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330525145
- Phone
- (858) 617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-31 | ABERNETHY MATT Chief Financial Officer | Option exercise 10b5-1 | +2,436 | 33,964 | ||
| 2025-01-31 | ABERNETHY MATT Chief Financial Officer | Sale 10b5-1 | −1,283 | $152.87 | $196K | 32,681 |
| 2025-01-31 | ABERNETHY MATT Chief Financial Officer | Option exercise · Restricted Stock Unit 10b5-1 | −2,436 | 2,437 | ||
| 2025-01-27 | GORMAN KEVIN CHARLES Director | Option exercise 10b5-1 | +146,105 | $32.99 | $4.8M | 660,701 |
| 2025-01-27 | GORMAN KEVIN CHARLES Director | Sale 10b5-1 | −146,105 | $149.46 | $21.8M | 514,596 |
| 2025-01-27 | GORMAN KEVIN CHARLES Director | Option exercise · Non-Qualified Stock Option 10b5-1 | −146,105 | 0 | ||
| 2025-01-15 | Gano Kyle Chief Executive Officer | Option exercise 10b5-1 | +4,812 | $32.99 | $159K | 140,204 |
| 2025-01-15 | Gano Kyle Chief Executive Officer | Sale 10b5-1 | −4,812 | $141.50 | $681K | 135,392 |
| 2025-01-15 | Gano Kyle Chief Executive Officer | Option exercise 10b5-1 | +60,188 | $32.99 | $2.0M | 195,580 |
| 2025-01-15 | Gano Kyle Chief Executive Officer | Sale 10b5-1 | −60,188 | $141.50 | $8.5M | 135,392 |
| 2025-01-15 | Gano Kyle Chief Executive Officer | Option exercise · Incentive Stock Option 10b5-1 | −4,812 | 0 | ||
| 2025-01-15 | Gano Kyle Chief Executive Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −60,188 | 0 | ||
| 2024-12-31 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 | +272 | $79.02 | $21K | 2,779 |
| 2024-12-31 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 | −272 | $138.10 | $38K | 2,507 |
| 2024-12-31 | Delaet Ingrid Chief Regulatory Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −272 | 2,718 | ||
| 2024-12-17 | ROBERTS EIRY Chief Medical Officer | Grant or award · Restricted Stock Unit | +5,487 | 5,487 | ||
| 2024-12-17 | ROBERTS EIRY Chief Medical Officer | Grant or award · Stock Option | +27,770 | 27,770 | ||
| 2024-12-17 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 | +1,091 | $79.02 | $86K | 3,598 |
| 2024-12-17 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 | −1,091 | $135.00 | $147K | 2,507 |
| 2024-12-17 | Delaet Ingrid Chief Regulatory Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −1,091 | 2,990 |
Page 27 of 49 · 963 trades